New combo aims to boost Radiation's power against tough pancreatic cancer

NCT ID NCT06141031

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a drug called TTI-101 combined with a precise type of radiation (SBRT) in 18 people with pancreatic cancer that is borderline resectable or locally advanced. The goal is to see if the combination is safe and can improve how long patients live without the cancer growing. The drug works by blocking a protein that may help tumors resist radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TTI-101 (a drug that blocks STAT3 protein) and stereotactic body radiation therapy (SBRT, a precise type of radiation)
What this could lead to: If this works, it could point toward a new combination treatment that improves survival for people with pancreatic cancer that hasn't spread.
What could go wrong: This is a very early, small Phase 1 trial with only 18 participants, so it's mainly checking safety and dosing. The treatment may not improve survival or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

University of Colorado
COMPLETED

Aurora, Colorado, 80045, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.